Development of a warning system for circulatory instability in critically ill patients

Submission date 27/01/2021	Recruitment status No longer recruiting	Prospectively registered
		☐ Protocol
Registration date 02/02/2021	Overall study status Completed	Statistical analysis plan
		Results
Last Edited	Condition category	Individual participant data
01/02/2021	Signs and Symptoms	Record updated in last year
aim of this study is	udy Aims ouptut is essential to tr	eat patients with shock in the intensive care unit. The letection of changes in cardiac output by means of a ary artery cathter
Who can participate? Adult patients with shock and a pulmonary artery catheter at the University Hospital Bern (Switzerland)		
What does the study involve? This observational study only collects routinely collected data. No additional study-specific measures are taken		
What are the possible benefits and risks of participating? None		
Where is the study run from? University Hospital Bern (Switzerland)		
When is the study starting and how long is it expected to run for? October 2017 to December 2021		
Who is funding the study? Edwards Lifesciences (Switzerland)		
Who is the main contact? Dr David Berger, david.berger@insel.ch		

Contact information

Type(s)Scientific

Contact name

Dr David Berger

ORCID ID

http://orcid.org/0000-0003-0705-6341

Contact details

Department of Intensive Care Medicine Inselspital University Hospital Bern Bern Switzerland 3010 +41 31 632 5079 david.berger@insel.ch

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

2018-00232

Study information

Scientific Title

Pulmonary artery pulse contour analysis in critically ill patients

Study objectives

The primary objective of this analysis is the evaluation of pulmonary artery pulse contour analysis to detect trends in cardiac output and pulmonary artery resistance and elastance. After establishing a routine for pulse contour analysis, respective stroke volumes will be compared with intermittent and continuous cardiac output.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 06/04/2018, Ethics Committee of the Swiss Canton of Bern (Kantonale Ethikkomission für die Forschung, Gesundheits- und Fürsorgerdirekton des Kanton Bern, Murtenstrasse 31, CH-3010 Bern

Switzerland; + 41 31 633 70 70; info.kek.kapa@gef.be.ch), ref: 2018-00232

Study design

Single center observational study

Primary study design

Observational

Secondary study design

Cohort study

Study setting(s)

Hospital

Study type(s)

Diagnostic

Participant information sheet

Health condition(s) or problem(s) studied

Shock

Interventions

Patients are eligible for the observational trial when they are monitored in the ICU by a pulmonary artery catheter. Hemodynamic data will be collected in real time for a period of 24 hours in addition to lab and clinical data. No specific interventions relate to the trial. The observation period is 24 hours maximum or until removal of the pulmonary artery catheter.

Intervention Type

Other

Primary outcome measure

Cardiac stroke volume measured using the pressure trace of the pulmonary artery collected using 24 hour ECG

Secondary outcome measures

There are no secondary outcome measures

Overall study start date

01/10/2017

Completion date

31/12/2021

Eligibility

Key inclusion criteria

Adult patients (age >= 18 years) treated on the participating intensive care unit for shock of any etiology monitored with a pulmonary artery catheter are eligible for inclusion

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

1,000

Key exclusion criteria

- 1. Patients/next of kin refusing to provide general consent
- 2. Mother tongue different from available general consent forms
- 3. Known pregnancy or breastfeeding
- 4. Patients institutionalized in correctional facilities
- 5. Patients institutionalized in psychiatric institutions

Date of first enrolment

08/06/2018

Date of final enrolment

21/12/2021

Locations

Countries of recruitment

Switzerland

Study participating centre University Hospital Bern

Department of Intensive Care Medicine Inselspital Freiburgstrasse Bern Switzerland 3010

Sponsor information

Organisation

Edwards Lifesciences (Switzerland)

Sponsor details

Route de l'Etraz 70 Nyon Switzerland 1260 +41 22 787 43 00 Teju Chaugule@edwards.com

Sponsor type

Industry

Website

http://www.edwards.com/ch-en

ROR

https://ror.org/012fexm34

Funder(s)

Funder type

Industry

Funder Name

Edwards Lifesciences

Alternative Name(s)

Edwards, Edwards Lifesciences Corporation, Edwards Lifesciences Corp., Edwards Lifesciences LLC, ELC

Funding Body Type

Government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

31/12/2022

Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date